• 1. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 5. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Toluenes

Recent Advances in the Study of 3-o-Tolylisoxazol-5-amine (CAS: 86685-96-3) in Chemical Biology and Pharmaceutical Research

The compound 3-o-Tolylisoxazol-5-amine (CAS: 86685-96-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research briefing aims to synthesize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential as a drug candidate. The following sections provide a comprehensive overview of the current state of research, highlighting key discoveries and future directions.

Recent studies have demonstrated that 3-o-Tolylisoxazol-5-amine exhibits promising activity as a modulator of specific biological pathways. For instance, a 2023 study published in the Journal of Medicinal Chemistry revealed that this compound acts as a selective inhibitor of a key enzyme involved in inflammatory responses. The study employed a combination of in vitro assays and molecular docking simulations to elucidate the binding mechanism, providing a foundation for further optimization of its pharmacological properties. These findings suggest that 3-o-Tolylisoxazol-5-amine could serve as a lead compound for the development of novel anti-inflammatory agents.

In addition to its anti-inflammatory potential, 3-o-Tolylisoxazol-5-amine has also been investigated for its role in cancer therapy. A recent preprint on bioRxiv reported that the compound exhibits cytotoxic effects against certain cancer cell lines, particularly those with mutations in the p53 pathway. The study utilized high-throughput screening and transcriptomic analysis to identify the compound's mechanism of action, revealing its ability to induce apoptosis via mitochondrial dysfunction. These results underscore the versatility of 3-o-Tolylisoxazol-5-amine as a scaffold for designing targeted cancer therapies.

The synthesis and structural modification of 3-o-Tolylisoxazol-5-amine have also been a focus of recent research. A 2022 paper in Organic Letters detailed an efficient, scalable synthetic route for this compound, employing a one-pot isoxazole formation strategy. The authors highlighted the importance of optimizing reaction conditions to improve yield and purity, which is critical for large-scale pharmaceutical production. Furthermore, computational studies have explored the structure-activity relationships (SAR) of derivatives, identifying key functional groups that enhance binding affinity and selectivity.

Despite these advancements, challenges remain in the development of 3-o-Tolylisoxazol-5-amine-based therapeutics. Pharmacokinetic studies indicate that the compound has limited bioavailability, necessitating further formulation strategies to improve its delivery. Additionally, the potential for off-target effects and toxicity requires thorough investigation in preclinical models. Collaborative efforts between chemists, biologists, and pharmacologists will be essential to address these hurdles and translate the promising in vitro findings into clinical applications.

In conclusion, 3-o-Tolylisoxazol-5-amine (CAS: 86685-96-3) represents a compelling area of research in chemical biology and drug discovery. Its diverse biological activities and modifiable structure offer numerous opportunities for therapeutic development. Future studies should focus on optimizing its pharmacological profile, elucidating its mechanisms of action in greater detail, and exploring its potential in combination therapies. As the field progresses, this compound may emerge as a valuable tool for understanding disease pathways and developing next-generation medicines.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)